Biocept Stock News

Biocept (NASDAQ:BIOC) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Thursday, Zacks.com reports. The brokerage currently has a $4.75 price objective on the medical research companys stock. Zacks Investment Researchs price target indicates a potential upside of 21.17% from the companys current price. []

Biocept (NASDAQ:BIOC) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Thursday, Zacks.com reports. The brokerage currently has a $4.75 target price on the medical research companys stock. Zacks Investment Researchs price objective points to a potential upside of 18.45% from the companys []

Biocept Inc (NASDAQ:BIOC) said it presented a study demonstrating the ability of its CNSide assay to identify HER2 and other actionable tumor alterations in the cerebrospinal fluid of patients with br

Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.

Major liquid biopsy market players include BIOCEPT, Inc., QIAGEN, Myriad Genetics, Inc., Lucence health Inc., Guardant Health, Inc. and F. Hoffmann-La Roche. Major liquid biopsy market players include BIOCEPT, Inc., QIAGEN, Myriad Genetics, Inc., Lucence health Inc., Guardant Health, Inc. and F. Hoffmann-La Roche.

TheStreet upgraded shares of Biocept (NASDAQ:BIOC) from a d rating to a c- rating in a research report sent to investors on Tuesday morning, TheStreetRatingsTable reports. Several other analysts have also issued reports on BIOC. Brookline Capital Acquisition restated a buy rating on shares of Biocept in a research note on Saturday, October 9th. Brookline []

The Gastric Cancer Diagnostics report published by Data Bridge Market research is the representation of data and analysis of the market. It gives detailed analysis of the current market scenario and a market forecast till 2028. The

Biocept, Inc. (NASDAQ:BIOC) was the recipient of a significant decrease in short interest during the month of October. As of October 29th, there was short interest totalling 461,900 shares, a decrease of 17.9% from the October 14th total of 562,900 shares. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is presently []

As Thanksgiving approaches, the U.S. death toll from COVID has now surpassed, in 2021, the total of 2020. Meanwhile, Europe leaders grow increasingly concerned.

SAN DIEGO--(BUSINESS WIRE)--Biocept launches combined COVID-19 and influenza test to help patients and caregivers determine treatment decisions during peak flu season.

Biocept Inc (NASDAQ:BIOC) said that it has started offering a single test that can detect and distinguish between SARS-CoV-2 and influenza, helping patients and caregivers determine appropriate treatm

SAN DIEGO--(BUSINESS WIRE)--Case series shows Biocept''s CNSide assay helps monitor treatment response and detects actionable biomarkers in patients with metastatic breast cancer.

Biocept Inc (NASDAQ:BIOC) will present a multi-institutional case series on its CNSide cerebrospinal fluid assay at the upcoming Society for Neuro-Oncology annual meeting in Boston. The San Diego-base

Biocept (NASDAQ:BIOC) posted its quarterly earnings data on Sunday. The medical research company reported $0.03 earnings per share for the quarter, missing the Thomson Reuters consensus estimate of $0.07 by ($0.04), MarketWatch Earnings reports. Biocept had a negative return on equity of 8.71% and a negative net margin of 4.02%. The business had revenue of []